Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Aug;390(8):769-774.
doi: 10.1007/s00210-017-1377-0. Epub 2017 Apr 20.

Inhibition of the CRF1 receptor influences the activity of antidepressant drugs in the forced swim test in rats

Affiliations

Inhibition of the CRF1 receptor influences the activity of antidepressant drugs in the forced swim test in rats

Andrzej Wróbel et al. Naunyn Schmiedebergs Arch Pharmacol. 2017 Aug.

Abstract

Hyperactivity of the hypothalamic-pituitary-adrenal axis (HPA) and impairment of the central corticotropin-releasing factor (CRF) system are factors in the pathogenesis of depression. Though several antagonists of the CRF1 receptor were effective in the recognized behavioral tests for antidepressant activity, there is still little information on the potential interactions between CRF1 receptor inhibitors and conventional antidepressant therapy. The aim of our study was to assess the influence of SN003, a CRF1 receptor blocker, on the activity of imipramine and fluoxetine in the forced swim test (FST) in rats which presented some signs of depression. The experiments were carried out on female Wistar rats subjected to 14-day subcutaneous corticosterone (CORT) administration (20 mg/kg/day). The antidepressant-like effect was determined by the FST and the CRF levels in the hypothalamus, amygdala, and peripheral blood were measured by a high-sensitivity immunoenzymatic test. SN003 (0.5 mg/kg) potentiated the antidepressant-like effect of imipramine (15 mg/kg) and fluoxetine (7.5 mg/kg). Moreover, the co-administration of the tested agents abolished CORT-induced increase in CRF levels in the examined biological material more profoundly than monotherapy. Our present findings give further evidence that the blockage of CRF action may be useful in the treatment of mood disorders. The concurrent use of well-known antidepressants with CRF1 receptor antagonists could be beneficial in terms of safety, since it requires lower doses of the applied agents.

Keywords: CRF1 receptor antagonist; Corticotropin-releasing factor level; Fluoxetine; Forced swim test; Imipramine; Rats.

PubMed Disclaimer

Conflict of interest statement

Funding

This study was supported by the Funds for Statutory Activity of the Medical University of Lublin, Poland.

Ethical approval

All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.

Conflict of interest

The authors declare that they have no conflicts of interest.

Figures

Fig. 1
Fig. 1
Effect of an acute administration of imipramine (IMI, 15 or 30 mg/kg), fluoxetine (FLX, 7.5 or 15 mg/kg), and SN003(0.5 or 1 mg/kg) on the behavior of rats subjected to 14-day corticosterone treatment (CORT, 20 mg/kg/day) in the forced swim test. The values represent the mean + SEM (n = 13–15 animals per group) after a single (a) or combined (b) injection. ***p < 0.001 versus saline; ^^^p < 0.001 versus CORT; +++ p < 0.001, ++ p < 0.01versus CORT plus SN003; ˅˅˅ p < 0.001, ˅˅ p < 0.01 versus CORT plus respective antidepressant drug (Dunnett’s or Newman-Keuls Multiple Comparison post hoc test)
Fig. 2
Fig. 2
Influence of an acute administration of imipramine (IMI, 15 or 30 mg/kg), fluoxetine (FLX, 7.5 or 15 mg/kg), and SN003 (0.5 or 1 mg/kg) on the locomotor activity of rats subjected to 14-day corticosterone treatment (CORT, 20 mg/kg/day). The values represent the mean + SEM (n = 13–15 animals per group)
Fig. 3
Fig. 3
Effect of an acute administration of imipramine (IMI, 15 or 30 mg/kg), fluoxetine (FLX, 7.5 or 15 mg/kg), and SN003(0.5 or 1 mg/kg) given as a single injection or in combination on the CRF levels in hypothalamus (a), amygdala (b), and peripheral blood (c) of rats subjected to 14-day corticosterone treatment (CORT, 20 mg/kg/day). The values represent the mean + SEM (n = 13–15 animals per group). ***p < 0.001 versus saline; ^^^p < 0.001, ^^p < 0.01, ^p < 0.05 versus CORT; +++ p < 0.001, ++ p < 0.01, + p < 0.05 versus CORT plus SN003; ˅˅˅ p < 0.001, ˅ p < 0.05 versus CORT plus respective antidepressant drug (Dunnett’s or Newman-Keuls Multiple Comparison post hoc test)

Similar articles

Cited by

References

    1. Arborelius L, Owens MJ, Plotsky PM, Nemeroff CB. The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol. 1999;160:1–12. doi: 10.1677/joe.0.1600001. - DOI - PubMed
    1. Bourke CH, Glasper ER, Neigh GN. SSRI or CRF antagonism partially ameliorate depressive-like behavior after adolescent social defeat. Behav Brain Res. 2014;270:295–299. doi: 10.1016/j.bbr.2014.05.035. - DOI - PubMed
    1. Chaki S, Nakazato A, Kennis L, Nakamura M, Mackie C, Sugiura M, Vinken P, Ashton D, Langlois X, Steckler T. Anxiolytic- and antidepressant-like profile of a new CRF1 receptor antagonist, R278995/CRA0450. Eur J Pharmacol. 2004;485:145–158. doi: 10.1016/j.ejphar.2003.11.032. - DOI - PubMed
    1. Chappell PB, Smith MA, Kilts CD, Bissette G, Ritchie J, Anderson C, Nemeroff CB. Alterations in corticotropin-releasing factor-like immunoreactivity in discrete rat brain regions after acute and chronic stress. J Neurosci. 1986;6:2908–2914. - PMC - PubMed
    1. De Bellis MD, Gold PW, Geracioti TD, Jr, Listwak SJ, Kling MA. Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression. Am J Psychiatry. 1993;150:656–657. doi: 10.1176/ajp.150.4.656. - DOI - PubMed

MeSH terms